Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 1686 • 2016 ACR/ARHP Annual Meeting
Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Diamant Thaci¹, Akimichi Morita², Julie Birt³, Chen-Yen Lin³, Catherine L. Shuler³ and Alice B. Gottlieb⁴, ¹Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ²Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴Tufts University School of Medicine, Boston, MA
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. In a phase 3 study, IXE was superior to placebo (PBO) in achieving…
Abstract Number: 1708 • 2016 ACR/ARHP Annual Meeting
Cutaneous Microbiota Features Distinguish Psoriasis from Psoriatic Arthritis
Julia Manasson¹, Soumya M. Reddy¹, Andrea L. Neimann², Leopoldo N. Segal³ and Jose U. Scher¹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Dermatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Pulmonary and Critical Care, New York University School of Medicine, New York City, NY
Background/Purpose: Psoriasis (PsO) is a chronic immune-mediated skin condition affecting ~3% of adults worldwide. Up to a third of PsO patients go on to…
Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Alan J. Kivitz¹, Kim Papp², Alim Devani³, Andreas Pinter⁴, Rodney Sinclair^5,6,7, Michael Ziv⁸, John Caminis⁹, Cass Kelleher¹⁰, Helen Tang¹¹, Barbara Finck¹⁰ and RaPsOdy study group , ¹Altoona Center for Clinical Research, Duncansville, PA, ²K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ³Institute for Skin Advancement, Surgical and Cosmetic Dermatology, Calgary, AB, Canada, ⁴Dept. of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt, Germany, ⁵University of Melbourne, E. Melbourne, Australia, ⁶Epworth Healthcare, E. Melbourne, Australia, ⁷Sinclair Dermatology Investigational Research, Education and Clinical Trials, E. Melbourne, Australia, ⁸Dept of Dermatology, Emek Medical Center, Afula, Israel, ⁹Shire, cambridge, MA, ¹⁰Clinical Science, Coherus BioSciences, Redwood City, CA, ¹¹Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…
Abstract Number: 1715 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses
Ben Klunder¹, Amit Khatri², Mukul Minocha³, Paul Peloso⁴ and Ahmed A. Othman², ¹AbbVie, Ludwigshafen am Rhein, Germany, ²AbbVie Inc., North Chicago, IL, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…
Abstract Number: 1724 • 2016 ACR/ARHP Annual Meeting
The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment
Majed Khraishi¹, Alice B. Gottlieb², Bengt Hoepken³, Luke Peterson⁴ and Philip J. Mease⁵, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Tufts University School of Medicine, Boston, MA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The majority of patients (pts) with psoriatic arthritis (PsA) experience psoriatic skin manifestations, which add to the already high burden of disease. The RAPID-PsA…
Abstract Number: 1725 • 2016 ACR/ARHP Annual Meeting
Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Samy Metyas¹, Ramy Messiah², Tina Gettas², Lisa Asfahani³ and Anne Quismorio⁴, ¹University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, USC, Covina, CA, ²Research Associate, Covina Arthritis Clinic, covina, CA, ³Physcian Assistant, Covina Arthritis Clinic, Covina, CA, ⁴Rheumatology, Covina Arthritis, Covina, CA
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 2164 • 2016 ACR/ARHP Annual Meeting
Depression and the Risk of Psoriatic Arthritis Among Patients with Psoriasis: A Population-Based Cohort Study
Ryan Lewinson^1,2, Isabelle Vallerand^1,3, Mark Lowerison³, Laurie Parsons⁴, Alexandra Frolkis^1,3, Gilaad Kaplan^3,4, Andrew Bulloch^3,5,6, Scott Patten^3,5 and Cheryl Barnabe^3,4, ¹Leaders in Medicine Program, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Biomedical Engineering Program, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ³Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Department of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Depression and the Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-based Cohort Study Background/Purpose: The factors that contribute to the development of psoriatic…
Abstract Number: 72 • 2016 ACR/ARHP Annual Meeting
Longitudinal Expression of CXCL10 in Psoriasis Patients That Develop Psoriatic Arthritis
Fatima Abji¹, Remy Pollock², Kun Liang³, Vinod Chandran⁴ and Dafna D Gladman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Longitudinal Expression of CXCL10 in Psoriasis Patients that Develop Psoriatic Arthritis Patients Fatima Abji1, Remy Pollock1 Kun Liang2, Vinod Chandran1,3, Dafna D. Gladman1,3 1University of…
Abstract Number: 2171 • 2016 ACR/ARHP Annual Meeting
Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared to Psoriasis Alone: Results from the UK Biobank
Eftychia Bellou¹, Suzanne M.M. Verstappen², Michael Cook³, Jamie C Sergeant^3,4, Richard B. Warren⁵, Anne Barton^1,4 and John Bowes¹, ¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁵Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with the presence of psoriasis. Both conditions are influenced by lifestyle factors such as alcohol…
Abstract Number: 149 • 2016 ACR/ARHP Annual Meeting
Comparation of Ultrasonic Imaging of Enthesopathy in the Lower Extremity in Patients with Psoriatic Arthritis, Psoriasis and Other Inflammatory Arthritis
Fei Sun¹ and Jian Zhu², ¹Chinese PLA General Hospital, Beijing, China, ²Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: To investigate the characteristics and differences of the ultrasonic imaging of enthesopathy in the lower extremity in patients with psoriatic arthritis(PsA), psoriasis(Ps) and other…
Abstract Number: 2443 • 2016 ACR/ARHP Annual Meeting
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study
Neda Amiri¹, Gretchen Bandoli² and Christina Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study Background/Purpose: While there is some evidence that women with psoriasis (Pso) and…
Abstract Number: 660 • 2015 ACR/ARHP Annual Meeting
Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]
Aman Sharma¹, Sushant Mishra², Sunil Dogra³ and Harish Kancharla², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Internal Medicine,, PGIMER,, Chandigarh, India, ³Department of Dermatology, PGIMER,, Chandigarh, India
Background/Purpose: Although there are various Psoriatic arthritis (PsA) screening questionnaires, the most optimal screening instrument is not known. The objective of the present study was…
Abstract Number: 673 • 2015 ACR/ARHP Annual Meeting
Characterization of Psoriatic Arthritis [Psa] in a Large, Integrated Health Plan: Demographics, Referral Patterns and Care Management
Vibeke Strand¹, Melody Chin², Arijit Ganguli³, Ridhima Nerlekar⁴, Victoria Kelly⁵, Daniel Chin⁶ and Alice Pressman⁴, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²University of California, San Francisco, San Francisco, CA, ³AbbVie Inc., North Chicago, IL, ⁴Research, Development, and Dissemination, Sutter Health, Walnut Creek, CA, ⁵Rheumatology, Palo Alto Medical Foundation, Palo Alto, CA, ⁶Clinical Evidence and Outcomes, AbbVie, North Chicago, IL
Background/Purpose: Despite guidelines and evidence indicating that early diagnosis and treatment of PsA is critical, few studies have described referral and care-management patterns in a…
Abstract Number: 1242 • 2015 ACR/ARHP Annual Meeting
Germ Line DNA Methylation Profiling Provides Novel Insights into the Parent-of-Origin Effect in Psoriatic Disease
Remy Pollock¹, Darren O'Reilly², Proton Rahman³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Parent-of-origin effects refer to the differential risk or pathogenicity of a disease that depends on the sex of the disease-transmitting parent. Excessive paternal transmission…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].